Young child plays with blocks

Autism

HEALTH INFORMATION

Investigating the effects of early intervention

WHAT WE KNOW

Autism spectrum disorders appear very early in a child’s life, generally before the age of three, and are characterised by problems in the following areas of development: social interaction, communication skills, and Individual children with autism spectrum disorders may present with very different sets of symptoms, and with widely varying degrees of severity.

Autism affects approximately 1 in 160 individuals, and is more common in males than females.  It is a neurodevelopmental disorder which usually appears very early, before the age of 3 years.   Symptoms of autism include problems in social communication, both verbal and non-verbal, difficulties understanding of what other people are feeling or thinking, and having restricted ranges of interest or difficulty tolerating change. Some level of intellectual disability frequently accompanies autism. Many individuals with autism also have problems with being either more or less sensitive to sensory stimuli such as sounds, light, and textures; difficulties with sleep; and high levels of anxiety or difficulty concentrating.

Autism is very heterogeneous, both in which symptoms most affect a person, and the severity of symptoms. While autism affects most people throughout their lifespan, the course can be quite different for different people, with some having significant improvement in symptoms as they get older, while other remaining unchanged or developing new problems such as seizures. People with autism can also develop other mental health problems, such as depression.

While we do not know exactly what causes autism, it likely comes about through a combination of genetic and environmental factors that affect the developing brain. Over a hundred different genes have been associated with the risk for autism. The current name “Autism Spectrum Disorders” reflects the likelihood that what we call autism probably represents a range of neurodevelopmental syndromes that may have different causes. One of the great challenges for research in autism is to try to better understand how differences between individuals with autism relate to how they respond to different kinds of interventions.

OUR LATEST RESEARCH

Identification and characterisation of ST8SIA2: a generalised mental illness susceptibility gene

Together with Professor Peter Schofield (NeuRA) and Professor Philip Mitchell (Black Dog Institute), our group is investigating the genetic contributors to bipolar disorder using Australian families with multiple individuals who have been diagnosed with the disorder.

The group previously identified a bipolar susceptibility locus located on chromosome 15 in a pooled analysis of 35 families. More detailed analysis of this region has identified a single gene, which confers an increased susceptibility to both bipolar disorder and schizophrenia, and has also been implicated as a risk factor for autism.

The group is now aiming to understand how alterations in ST8SIA2 translate into an increased genetic susceptibility by characterising alterations in the DNA, RNA and protein product of this gene and its interaction partners in patients with either bipolar disorder or schizophrenia.

A functional near-infrared spectroscopy study of early intervention for children with autism

The aim of this study is to determine whether the Early Start Denver Model (ESDM), an early intervention program for preschool aged children with autism, affects developmental changes in brain activity.

An MRI study of intervention outcomes in children with autism

The proposed study will evaluate primary school aged children with Autism Spectrum Disorders to determine whether baseline measures of brain structure and function can contribute to predict response to interventions such as school based programs.

What else is happening in Autism research at NeuRA?

FEEL THE BUZZ IN THE AIR? US TOO.

The cold case of schizophrenia - broken wide open!

‘It is like they were miraculously healed!’’ Schizophrenia is diagnosed by clinical observation of behaviour and speech. This is why NeuRA researchers are working hard to understand the biological basis of the illness. Through hours of work and in collaboration with doctors and scientists here and around the world, NeuRA has made an amazing breakthrough. For the first time, researchers have discovered the presence of antibodies in the brains of people who lived with schizophrenia. Having found these antibodies, it has led NeuRA researchers to ask two questions. What are they doing there? What should we do about the antibodies– help or remove them? This is a key breakthrough. Imagine if we are treating schizophrenia all wrong! It is early days, but can you imagine the treatment implications if we’ve identified a new biological basis for the disease? It could completely change the way schizophrenia is managed, creating new treatments that will protect the brain. More than this, could we be on the verge of discovering a ‘curable’ form of schizophrenia? How you can help We are so grateful for your loyal support of schizophrenia research in Australia, and today I ask if you will consider a gift today. Or, to provide greater confidence, consider becoming a Discovery Partner by making a monthly commitment. We believe there is great potential to explore these findings. Will you help move today’s breakthrough into tomorrow’s cure? To read more about this breakthrough, click ‘read the full story’ below. You are also invited to read ‘Beth’s story’, whose sweet son Marcus lived with schizophrenia, by clicking here.
APPEAL